Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase

Liu, Nathan; Chapman, Robert; Lin, Yiyang; Bentham, Andrew; Tyreman, Matthew; Philips, Natalie; Khan, Shahid A.; Stevens, Molly M.

doi:10.1039/c6nr03376h

Cited by 8 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many factors, such as oxygen free radicals, NF-κB, nitric oxide (NO), cytokines and arachidonic acid metabolites may be related to AHNP and ALI. 27,28 L-arginine (an essential amino acid) was previously used to induce severe necrotizing AP in rats. Uçmak et al, 29 revealed that intraperitoneal injection of L-arginine induced acute pancreatitis in a rat by creating free oxygen radicals that damage the pancreas.…”

Section: Discussionmentioning

confidence: 99%

Untitled

2020

IJMBOA

View full text Add to dashboard Cite

Introduction: Acute pancreatitis (AP) is a disease that results in inflammation of the pancreatic tissue. The most characteristic features of this disease are activation of digestive enzymes such as amylase and lipase with subsequent release of pro-inflammatory cytokines. It may be complicated with multiorgan failure. Pulmonary complications are considered the most frequent and most serious complications. Apitherapy is a type of natural medicine that uses honey bee products like bee venom and bee propolis for treating various diseases.The aim of the study: To elucidate the apitherapeutic value of bee venom and bee propolis on L-arginine-induced acute pancreatitis and its associated lung injury complication in adult male albino rats via biological study. Materials and methods:This study was performed on 70 adult male albino rats. Rats were randomly divided into seven groups: Group I :Control group (CG), Group II :Acute pancreatitis group (AP) in which pancreatitis was induced by two intraperitoneal (i.p.) injections of 2g/kg L-arginine, 1 h apart, Group III :Bee venom (250µg/kg subcutaneous (s.c.) injection) + L-arginine treated group (BVL), Group IV: Bee propolis (300mg/kg intramuscular (i.m.) injection) + L-arginine treated group (BPL), Group V: Combined therapy group (CT), Group VI: Bee venom only treated group(BV) and Group VII: Bee propolis only treated group (BP). The diagnostic markers, including serum lipase and amylase, GGT, glucose, CRP, tissue total antioxidants and RT-PCR analysis of matrix metalloproteinase-9 (MMP-9), were measured. Histological (using hematoxylin & eosin stain) and Immunohistochemical (using NF-κB immunostain) techniques were done. The morphometric study was performed for area % and optical density of immunoexpression of NF-κB in pancreatic and lung tissues. All performed measurements were followed by statistical analysis.Results: Acute pancreatitis group revealed a significant increase in amylase and lipase serum levels, increase in MMP-9 expression and a decrease in the total antioxidants tissue content. Histopathological results demonstrated widening of the connective tissue septa of the pancreas with degeneration of pancreatic acini in AP group while, the lungs showed thickened interalveolar septa with inflammatory cellular infiltration. A significant increase in immunoreactivity of NF-κB in pancreatic and lung tissues was also observed. The pretreated groups showed a significant improvement of these biochemical and histological changes.Conclusions: There was a significant role of pretreatment with bee venom and bee propolis in ameliorating biochemical and histopathological changes in AP group.

show abstract

Section: Discussionmentioning

confidence: 99%

Untitled

2020

IJMBOA

View full text Add to dashboard Cite

show abstract

“…Our development of NP-based biosensors has yielded assays for a variety of noninfectious disease targets over the years, including cancer, pancreatitis, , arthritis, blood coagulation, prostate-related diseases, and cardiovascular disease . During this time, our attention began to turn to the threat of infectious diseases, as it was apparent that issues such as the increasing prevalence of antimicrobial resistance and the risk of zoonotic or mutant-driven pandemics were not being matched by an increase in invention and translation of viable and field-deployable IVD devices.…”

Section: Toward Infectious Disease Diagnostics At the Point-of-care U...mentioning

confidence: 99%

Noble Metal Nanoparticle Biosensors: From Fundamental Studies toward Point-of-Care Diagnostics

Geng

Pedersen

et al. 2022

Acc. Chem. Res.

Self Cite

View full text Add to dashboard Cite

Conspectus Noble metal nanoparticles (NMNPs) have become firmly established as effective agents to detect various biomolecules with extremely high sensitivity. This ability stems from the collective oscillation of free electrons and extremely large electric field enhancement under exposure to light, leading to various light–matter interactions such as localized surface plasmon resonance (LSPR) and surface-enhanced Raman scattering. A remarkable feature of NMNPs is their customizability by mechanisms such as particle etching, growth, and aggregation/dispersion, yielding distinct color changes and excellent opportunities for colorimetric biosensing in user-friendly assays and devices. They are readily functionalized with a large variety of capping agents and biomolecules, with resultant bioconjugates often possessing excellent biocompatibility, which can be used to quantitatively detect analytes from physiological fluids. Furthermore, they can possess excellent catalytic properties that can achieve significant signal amplification through mechanisms such as the catalytic transformation of colorless substrates to colored reporters. The various excellent attributes of NMNP biosensors have put them in the spotlight for developing high-performance in vitro diagnostic (IVD) devices that are particularly well-suited to mitigate the societal threat that infectious diseases pose. This threat continues to dominate the global health care landscape, claiming millions of lives annually. NMNP IVDs possess the potential to sensitively detect infections even at very early stages with affordable and field-deployable devices, which will be key to strengthening infectious disease management. This has been the major focal point of current research, with a view to new avenues for early multiplexed detection of infectious diseases with portable devices such as smartphones, especially in resource-limited settings. In this Account, we provide an overview of our original inspiration and efforts in NMNP-based assay development, together with some more sophisticated IVD assays by ourselves and many others. Our work in the area has led to our recent efforts in developing IVDs for high-profile infectious diseases, including Ebola and HIV. We emphasize that integration with digital platforms represents an opportunity to establish and efficiently manage widespread testing, tracking, epidemiological intelligence, and data sharing backed by community participation. We highlight how digital technologies can address the limitations of conventional diagnostic technologies at the point of care (POC) and how they may be used to abate and contain the spread of infectious diseases. Finally, we focus on more recent integrations of noble metal nanoparticles with Raman spectroscopy for accurate, noninvasive POC diagnostics with improved sensitivity and specificity.

show abstract

“…Phospholipases A2 (PLA2) and sPLA2-IB 46,47 Lateral flow assay 46,47 Optical detection 46,47 Serum interleukin-8 (IL-8) 48 Microfluidic chip with magnetic beads Chemiluminescent assay Serum Typtophan 49 Aptamer-based Electrochemical biosensor Serum, saliva and urine Anticoagulants, unfractionated herapin and low molecular weight herapin 50…”

Section: Serummentioning

confidence: 99%

“…Despite ubiquity, monitoring glucose in blood is invasive. Hence, noninvasive glucose sensing 33 nucleic acid sequencing 33,34 plasma 35,36 stainless steel wires 34 picogreen assay for DNA 35,36 polypyrrole nanochip 35,36 exosomes 37 immunomagnetic beads optical fluorescence blood plasma C-reactive protein 38,39 oriented capture antibody 38 surface plasmon resonance (SPR)-based 39 blood paper-based device 39 enzyme-linked immunosorbent assay (ELISA) 39 α-fetoprotein 40 microsensor chip microring resonators whole blood hepatitis B virus genome 41 magnetic nanoparticles quantum dot barcode technology with optical readout patient serum carcinoembryonic antigen 40,42 microsensor chip 40 microring resonators 40 whole serum microspheres 42 optical trapping and two-photon excitation fluorescence 42 parathyroid hormone-related peptide 31 magnetic beads multiplexed peptide assay human serum tumor-associated antigens 43 capture antibodies nanoplasmonic biosensor serum or plasma serum ferritin for iron status 44 lateral flow immunoassay mobile device-coupled blood finger prick prostate specific antigen (PSA) 30,40,45 magnetic beads 30 SERS nanotags and Raman spectroscopy 30 serum microsensor chip 40 microring resonators 40 microcontact imprinted chips 45 surface plasmon resonance (SPR) biosensor 45 phospholipases A2 (PLA 2 ) and sPLA 2 -IB 46,47 lateral flow assay 46,47 optical detection 46,…”

Section: ■ Bloodmentioning

confidence: 99%